Additional androgen deprivation makes the difference

  title={Additional androgen deprivation makes the difference},
  author={J. Schiffmann and Hans Lesmana and P. Tennstedt and B. Beyer and K. Boehm and V. Platz and D. Tilki and G. Salomon and C. Petersen and A. Kr{\"u}ll and M. Graefen and R. Schwarz},
  journal={Strahlentherapie und Onkologie},
  • J. Schiffmann, Hans Lesmana, +9 authors R. Schwarz
  • Published 2014
  • Medicine
  • Strahlentherapie und Onkologie
  • BackgroundThe role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown.Patients and methodsConsecutive PCa patients classified as D’Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were… CONTINUE READING
    12 Citations
    Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy
    • 16
    High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.
    • 18
    Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?
    • 17
    PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator
    • 7


    Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
    • 344
    Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
    • A. D'Amico, B. J. Moran, +5 authors M. Chen
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 70
    • Highly Influential
    Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    • 825